ReviewFrontiers in molecular neuroscience2025
LncRNA-driven programmed cell death networks: new therapeutic targets for neurological disorders.
Review in Frontiers in molecular neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bridging development and disease: the potential of LncRNAs as biomarkers and therapeutics in pediatric neurological disorders.Pediatric research · 2026Review
- The LINC00968/miR-194-5p Axis Exacerbates Neurological Dysfunction After Intracerebral Hemorrhage by Regulating Oxidative Stress and Neuroinflammation.Neurochemical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neural cell death is a critical pathological mechanism underlying the development and progression of central nervous system (CNS) diseases, where programmed cell death (PCD) pathways serve as critical regulatory hubs. In addition to classical apoptosis and autophagy, emerging PCD modalities including necroptosis, pyroptosis, ferroptosis, and cuproptosis exhibit distinct activation patterns in different neurological diseases. Long non-coding RNAs (lncRNAs) have emerged as pivotal regulators of these PCD processes through multiple molecular strategies by modulating chromatin accessibility, assembling signaling complexes, and regulating post-transcriptional processes. These regulatory interactions vary by cellular location and disease stage, influencing cell fate through membrane receptors, kinase cascades, and nuclear transcriptional programs. In various CNS pathologies, specific lncRNAs display dual regulatory capacities-promoting neuronal death by amplifying cytotoxic signals or conferring neuroprotection by inhibiting these pathways. The dynamic lncRNA-PCD interactions offer therapeutic potential through targeted modulation of lncRNA networks to control neuronal survival. Future investigations should prioritize systematic mapping of context-specific lncRNA regulatory networks governing distinct PCD modalities, concurrently advancing spatial epigenomic editing technologies for precise manipulation of these regulatory circuits. Understanding these molecular interactions better will help identify therapeutic targets and guide CNS drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.